[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphedema-of-upper-arm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphedema-of-upper-arm":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,84,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":36,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100053937","screening-for-bcrl-in-targeted-therapy-for-breast-cancer-100053937",false,"NCT05142800","Screening For BCRL In Targeted Therapy For Breast Cancer","Screening for Edema and Breast Cancer-Related Lymphedema in Patients Undergoing Targeted Therapy for Breast Cancer","Inclusion Criteria:\n\n* Subjects who are receiving treatment in the MGH Breast Cancer Center who are enrolled in a DF\u002FHCC-regulated targeted therapy trial for the treatment of early or metastatic breast cancer or patients being treated with a targeted therapy that may alter their risk of developing edema or BCRL will be eligible.\n* Subjects that will be eligible for the study include:\n* Females between 18 and 80 years of age\n* With a history of breast cancer\n* 4 weeks or more post-surgery\n* With or without edema\n* Undergoing treatment with targeted therapy for early or metastatic disease.\n\nExclusion Criteria:\n\n\\- Patients who cannot attain 90 degrees of shoulder abduction (position of measurement with Perometer).","FEMALE","18 Years","80 Years",{"count":20,"type":21},261,"ESTIMATED","OBSERVATIONAL","This a prospective, longitudinal study designed to track edema and Breast Cancer Related Lymphedema (BCRL) onset in breast cancer patients taking targeted therapy treatments for early and metastatic breast cancer.\n\nA Perometer and Sozo devise will be used to measure volume changes",[25,26,27,28,29,30,31,32,33,34,35],"Lymphedema","Lymphedema Arm","Lymphedema of Upper Arm","Lymphedema of Upper Limb","Lymphedema of the Hands","Edema","Edema Arm","Breast Cancer Lymphedema","Breast Cancer Metastatic","Breast Cancer Stage","Breast Cancer",[25,26,27,28,29,30,31,32,33,34,35],"RECRUITING","2026-07-09",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":41},"2018-12-13",{"date":45,"type":21},"2026-09-30",{"name":47,"class":48},"Massachusetts General Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},"100527161","phase-3-a-study-of-a-comprehensive-prevention-program-to-reduce-lymphedema-after-axillary-lymph-node-dissection-in-people-with-breast-cancer-100527161","NCT06144164","A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer","A Prospective Cohort Study of Patients Undergoing ALND for Treatment of Breast Cancer: The Efficacy of a Comprehensive Prevention Program in Decreasing the Incidence of Lymphedema and Improving Quality of Life","Inclusion Criteria:\n\n* Female sex\n* Diagnosis of breast cancer\n* Ages 18 to 75 years\n* Consented for unilateral ALND or for unilateral SLNB with possible ALND\n\nExclusion Criteria:\n\n* Male sex\n* Does not speak English\n* Does not fit into study garment\n* Axillary recurrence\n* History of ALND\n* Requirement of bilateral ALND for the treatment of breast cancer\n* Treatment with SLNB only\n* Known anaphylactic allergy to ICG dye used in ILR\n* Impaired decision-making capacity","75 Years",{"count":59,"type":21},285,"INTERVENTIONAL",[62],"PHASE3","The purpose of this study to test whether a comprehensive program may help the lymph fluid to drain out of the arm and prevent lymphedema in participants with breast cancer.",[25,26,27,35,65,66],"Breast Carcinoma","Female Breast Cancer",[68,69,25,26,27,70,71,72,73,74],"immediate lymphatic reconstruction","axillary lymph node dissection","Breast cancer","breast carcinoma","female breast cancer","Memorial Sloan Kettering Cancer Center","23-303","2025-11-06",{"date":77,"type":41},"2025-11-10",{"date":79,"type":41},"2023-11-16",{"date":81,"type":21},"2030-03-16",{"name":73,"class":48},7,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":60,"phases":93,"briefSummary":95,"conditions":96,"keywords":102,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":49},"100557041","the-robot-lva-study-robot-assisted-microsurgical-lymphaticovenous-anastomosis-in-breast-cancer-related-lymphedema-100557041","NCT06532955","The Robot-LVA Study: Robot-assisted Microsurgical Lymphaticovenous Anastomosis in Breast Cancer-related Lymphedema","Pilot Study on Robotic Assisted Microsurgical Lymphatico-venular Anastomosis","Inclusion Criteria:\n\n* Female gender;\n* Treated for primary early stage breast cancer;\n* Early stage lymphedema of the arm (stage 1 or 2 on ISL classification);\n* ELV \\> 10%;\n* Suffering from unilateral disease.\n\nExclusion Criteria:\n\n* Male gender;\n* Stage 3 lymphedema of the arm;\n* Receiving current breast cancer treatment;\n* Distant breast cancer metastases;\n* Current substance abuse;\n* History of marcaine or indocyanine green allergy;\n* Non-viable lymphatic system as determined by near infrared imaging;\n* Previous LVA (\\\u003C10 years) in the arm with lymphedema.",{"count":92,"type":21},60,[94],"NA","This study assesses the performance of robot-assisted microsurgery. Lymphaticovenous anastomosis (LVA) is the most difficult procedure in microsurgery at this moment. The LVA technique is applied to treat for example breast cancer-related lymphedema (BCRL). Therefore, this LVA procedure is compared using a manual expert and the same expert applying robot-assisted LVA.",[25,26,27,28,97,98,99,100,101],"Lymphedema; Surgical","Lymphedema, Secondary","Lymphedema of Limb","Lymphedema, Breast Cancer","Lymphedema, Non-Filarial",[103,104,105,106,107,108,109,110],"Robot-assisted microsurgery","Microsurgery","Robot","Robotic-assisted","Robot-assisted","Lymphaticovenous anastomosis","Lymphatico-venular anastomosis","LVA","2024-07-30",{"date":113,"type":41},"2024-08-01",{"date":115,"type":41},"2017-06-01",{"date":117,"type":21},"2026-01-01",{"name":119,"class":48},"Maastricht University Medical Center",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":60,"phases":130,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":145},"100415500","photobiomodulation-therapy-for-the-management-of-breast-cancer-related-lymphedema-100415500","NCT04690439","Photobiomodulation Therapy for the Management of Breast Cancer-related Lymphedema","Evaluating the Effectiveness of Photobiomodulation Therapy in the Management of Breast Cancer-Related Lymphedema: a Randomized Controlled Trial","LymphLight","Inclusion Criteria:\n\n* Diagnosed with breast cancer\n* Underwent ipsilateral lumpectomy or mastectomy + sentinel lymph node biopsy +\u002F- lymph node dissection\n* Underwent radiotherapy with or without chemotherapy\n* Diagnosed with BCRL (i.e. International Society of Lymphology (ISL) lymphedema stage I or higher)\n* Age ≥ 18 years\n* Able to comply to the study protocol\n* Able to sign written informed consent\n\nExclusion Criteria:\n\n* Metastatic disease\n* Pregnancy\n* History of surgery or trauma to the arm\n* History of arm infection in the past 3 months\n* Use of medications that affect body fluid (e.g., diuretics) in the last 3 months\n* Severe psychological disorder or dementia\n* Any condition that is unstable or could affect the safety of the patient and their compliance in the study as judged by the investigator",{"count":129,"type":21},104,[94],"Up to one out of five patients with breast cancer will develop lymphedema in the upper extremity after cancer treatment. Patients with breast cancer-related lymphedema (BCRL) suffer from pain, heaviness, tightness, and a decreased range of motion. Photobiomodulation therapy (PBMT) is a non-invasive therapy based on the application of visible and\u002For near-infrared light produced by a laser diode or a light-emitting diode. The scientifically proven biologic effects of PBM are improved wound healing, and a reduction in pain, inflammation, and oedema. Therefore, the aim of this study is to evaluate the effectiveness of PBMT on the management of BCRL.",[35,133,27],"Breast Cancer Related Lymphedema",[25,70,135],"Photobiomodulation","2023-02-27",{"date":138,"type":41},"2023-02-28",{"date":140,"type":41},"2021-02-22",{"date":142,"type":21},"2028-02",{"name":144,"class":48},"Jessa Hospital",2]